+1 to Dr.NateNeph. Especially the point about "Re: GLP-1 therapy in patients over — the..." — I have seen the same in my own experience with GLP-1 therapy in patients.
Want to share my personal experience related to GLP-1 therapy in patients over since I think it might help others in a similar situation.
I started my GLP-1 journey in March 2025 at 261 lbs with metabolic syndrome. My telehealth provider prescribed semaglutide 0.25mg to start.
Now, 14 months later: I am down 71 lbs, my labs have normalized, and my sleep apnea has improved dramatically. The GLP-1 therapy in aspect specifically was something that made a big difference in my journey.
This forum was my go-to resource throughout.
GenomicsKate — that is really helpful context on GLP-1 therapy in patients. Follow-up question: did you change anything about your diet at the same time?
I am in a similar situation (month 2) and trying to set realistic expectations.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsTo answer mel_PDX's question specifically:
From a clinical standpoint, GLP-1 therapy in patients over is well-supported by the literature.
The short answer: follow the standard titration protocol and reassess at 4-6 weeks.
The longer answer involves pharmacokinetic considerations around steady-state concentrations, which I am happy to elaborate on if helpful.
Saving this for reference. Top-tier content.